Lilly’s Multi-Tumor Treatment Retsevmo Closer To EU Approval
Set For First-In-Class Status
Executive Summary
Approved in the US in May, the drug is the latest targeted therapy to emerge from Lilly’s oncology division Loxo.
You may also be interested in...
LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
Caribou Prepares To Unveil Data On PD-1 Knock Out CAR-T
Proof of concept for Caribou’s gene-editing tweaks is just around the corner, but competition is intense in the allogeneic CAR-T field.
Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy
After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.